Synthesis, characterization, molecular docking and biological evaluation of novel 6-halo-2-(4-((5-phenyl-1, 3, 4-oxadiazol-2-yl)methoxy)Substituted phenyl)-1 H-benzo[de]isoquinoline-1,3(2H)-dione

Abstract

A new series of 2-(4-((5-(4-bromophenyl)-1, 3, 4-oxadiazol-2-yl)methoxy)phenyl)-1 H -benzo[ de ] isoquinoline-1,3(2 H )-dione derivatives ( 6a-l ) have been synthesized by using conventional method. All the newly synthesized compounds were evaluated for their antibacterial and antifungal activity four bacterial strains Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa . Ciprofloxacin used standard drug. The antifungal activity screened against two pathogenic fungal strains Aspergillus niger and Candida albicans and Voriconazole used as standard drug. The antibacterial results shows that compounds 6i more than 6f are as potent against S. aureus with compare to standard drug. In the case of B. subtilis the compounds 6f more than 6i are more active. In the case of E. coli the compounds 6i more than 6f are more active. The compounds 6f and 6i are more active against P. aeruginosa . The anti-fungal activity result shows that the compounds 6f and 6i are as active as standard drug Voriconazole against A. niger . In the case of C. albicans the compounds 6f and 6i are showing the same activity with compare to standard drug. All the synthesized novel compounds were characterized by FTIR, 1 H NMR, 13 C NMR, HRMS spectroscopic methods and the elemental analysis (C, H and N).